Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1040 |
Name | chronic lymphocytic leukemia |
Definition | A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ATR over exp | Ceralasertib | chronic lymphocytic leukemia | predicted - sensitive | detail... |
TP53 mutant | Duvelisib | chronic lymphocytic leukemia | predicted - sensitive | detail... |
TP53 inact mut | AZD6482 | chronic lymphocytic leukemia | predicted - sensitive | detail... |
ATM loss | AZD6482 | chronic lymphocytic leukemia | sensitive | detail... |
TP53 inact mut | Ceralasertib + Ibrutinib | chronic lymphocytic leukemia | sensitive | detail... |
ATM loss | Ceralasertib + Ibrutinib | chronic lymphocytic leukemia | sensitive | detail... |
ATM inact mut | Olaparib | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Ibrutinib + Venetoclax | chronic lymphocytic leukemia | predicted - sensitive | detail... |
TP53 mutant | CG-806 | chronic lymphocytic leukemia | predicted - sensitive | detail... |
BRAF K601N | PLX8394 | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Ibrutinib | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Acalabrutinib | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Obinutuzumab + Venetoclax | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Venetoclax | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Idelalisib + Rituximab | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Zanubrutinib | chronic lymphocytic leukemia | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00577278 | Phase II | Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | Completed | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00829647 | Phase Ib/II | Dasatinib + Lenalidomide | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | Withdrawn | 0 | |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Completed | USA | TUR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | BRA | BEL | ARG | 5 |
NCT01087294 | Phase I | Anti-CD19 CAR-T cells | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT01125176 | Phase II | Lenalidomide + Rituximab + Thalidomide | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL | Completed | USA | 0 |
NCT01173679 | Phase II | Dasatinib + Fludarabine + Rituximab | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Terminated | USA | 0 |
NCT01193842 | Phase Ib/II | Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Completed | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01296932 | Phase I | BI 836826 | BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) | Completed | FRA | DEU | BEL | 0 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01441882 | Phase II | Dasatinib | A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity | Completed | USA | 0 |
NCT01459211 | Phase II | Dexamethasone Lenalidomide | Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) | Completed | GBR | 0 |
NCT01532700 | Phase II | Afuresertib + Ofatumumab | An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) | Completed | CAN | 0 |
NCT01556776 | Phase III | Lenalidomide | A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy | Completed | DEU | 0 |
NCT01604031 | Phase Ib/II | Lenalidomide | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide | Terminated | USA | 0 |
NCT01638533 | Phase I | Romidepsin | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | Active, not recruiting | USA | CAN | 0 |
NCT01644253 | Phase I | Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Bendamustine + Otlertuzumab | Phase 1b Safety and Efficacy Study of TRU-016 | Terminated | USA | 0 |
NCT01660451 | Phase II | Copanlisib | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | Completed | USA | TUR | SWE | POL | NZL | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BGR | BEL | AUT | AUS | 5 |
NCT01671904 | Phase I | Bendamustine + Obinutuzumab + Venetoclax Bendamustine + Rituximab + Venetoclax | A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia | Completed | USA | FRA | DEU | 0 |
NCT01685892 | Phase I | Obinutuzumab + Venetoclax | A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia | Completed | USA | GBR | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DNK | DEU | 0 |
NCT01732913 | Phase III | Idelalisib Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | AUS | 6 |
NCT01732926 | Phase III | Idelalisib Bendamustine + Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | SWE | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 3 |
NCT01750567 | Phase II | Metformin | A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL | Active, not recruiting | USA | 0 |
NCT01799889 | Phase II | Entospletinib | A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Enrolling by invitation | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT01849276 | Phase I | Cytarabine + Metformin | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Terminated | USA | 0 |
NCT01853631 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Recruiting | USA | 0 |
NCT01885897 | Phase Ib/II | Nogapendekin alfa inbakicept | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
NCT01889186 | Phase II | Venetoclax | A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion | Completed | USA | POL | GBR | FRA | DEU | CAN | AUS | 0 |
NCT01905813 | Phase I | Dezapelisib + Itacitinib Dezapelisib | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT01980875 | Phase III | Idelalisib + Obinutuzumab Chlorambucil + Obinutuzumab | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | Terminated | USA | POL | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01980888 | Phase III | Bendamustine + Idelalisib + Rituximab | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia | Terminated | USA | ROU | POL | ITA | HUN | HRV | GBR | FRA | ESP | CZE | CAN | BEL | AUS | 0 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02004522 | Phase III | Duvelisib Ofatumumab | A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | Completed | USA | NZL | ITA | HUN | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 0 |
NCT02005289 | Phase II | Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | Active, not recruiting | USA | 0 |
NCT02005471 | Phase III | Venetoclax Bendamustine Rituximab | A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Completed | USA | SWE | POL | NZL | NLD | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | 3 |
NCT02015208 | Phase Ib/II | Ruxolitinib | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | Completed | CAN | 0 |
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Completed | USA | 0 |
NCT02044822 | Phase II | Idelalisib + Rituximab | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | Terminated | USA | ROU | POL | ITA | HUN | GBR | FRA | ESP | DNK | CZE | BEL | AUT | AUS | 1 |
NCT02049515 | Phase III | Ofatumumab Duvelisib | A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 | Completed | USA | NZL | ITA | HUN | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 0 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Completed | USA | CAN | 0 |
NCT02100423 | Phase II | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Completed | USA | 0 | |
NCT02100852 | Phase I | Chlorambucil + Obinutuzumab + Umbralisib | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02131584 | Phase II | Ruxolitinib | Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | 0 |
NCT02135133 | Phase II | Idelalisib + Ofatumumab | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | Completed | USA | 0 |
NCT02141282 | Phase II | Venetoclax | A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy | Completed | USA | 0 |
NCT02158091 | Phase Ib/II | Cyclophosphamide + Fludarabine + Rituximab Duvelisib | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | Active, not recruiting | USA | 0 |
NCT02160015 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02200848 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL | Terminated | USA | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02222688 | Phase I | Cirmtuzumab | UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT02242942 | Phase III | Chlorambucil + Obinutuzumab Obinutuzumab + Venetoclax | A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ROU | POL | NZL | ITA | HRV | GBR | FRA | EST | ESP | DNK | DEU | CHE | CAN | BRA | BGR | AUT | AUS | ARG | 2 |
NCT02249429 | Phase Ib/II | PQR309 | Open-Label, Non Randomized Phase 2 Study With Safety Run-In | Completed | USA | ISR | GBR | FRA | 2 |
NCT02251548 | Phase II | Cyclophosphamide + Fludarabine + Ibrutinib + Rituximab | A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02268851 | Phase I | Ibrutinib + Umbralisib | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | Completed | USA | 0 |
NCT02285244 | Phase II | Sotrastaurin | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | Withdrawn | 0 | |
NCT02292225 | Phase I | Duvelisib + Obinutuzumab | IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi | Terminated | USA | CAN | 0 |
NCT02296918 | Phase I | Acalabrutinib + Obinutuzumab | ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL | Active, not recruiting | USA | 0 |
NCT02301156 | Phase III | Ibrutinib + Ublituximab Ibrutinib | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | Completed | USA | ISR | 0 |
NCT02303392 | Phase I | Ibrutinib + Selinexor | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT02315768 | Phase Ib/II | Ibrutinib + Obinutuzumab | Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | Active, not recruiting | USA | 0 |
NCT02319369 | Phase I | Milademetan | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies | Terminated | USA | 0 |
NCT02332980 | Phase II | Pembrolizumab | A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02340780 | Phase II | Buparlisib | Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia | Completed | CAN | 0 |
NCT02361346 | Phase Ib/II | MT-3724 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) | Terminated | USA | POL | ISR | ESP | CAN | 5 |
NCT02369016 | Phase III | Copanlisib | Phase III Copanlisib in Rituximab-refractory iNHL | Completed | TUR | POL | ITA | GRC | BRA | BGR | 4 |
NCT02420912 | Phase II | Ibrutinib + Nivolumab | Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02427451 | Phase Ib/II | Ibrutinib + Obinutuzumab + Venetoclax | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | ARG | 0 |
NCT02454270 | Phase II | JNJ-64052781 | A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies | Terminated | USA | ISR | FRA | ESP | BEL | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Terminated | USA | GBR | FRA | 0 |
NCT02475681 | Phase III | Acalabrutinib Chlorambucil Obinutuzumab | Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL | Active, not recruiting | USA | SWE | POL | NZL | LTU | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 2 |
NCT02477696 | Phase III | Acalabrutinib Ibrutinib | Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia | Active, not recruiting | USA | TUR | POL | NZL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | BEL | AUS | 0 |
NCT02514083 | Phase II | Fludarabine + Ibrutinib | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | Active, not recruiting | USA | 0 |
NCT02529813 | Phase I | Cyclophosphamide + Fludarabine + Tisagenlecleucel | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | USA | 0 |
NCT02535286 | Phase Ib/II | Pembrolizumab + Ublituximab + Umbralisib | Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL | Completed | USA | 0 |
NCT02537613 | Phase I | Ibrutinib + Obinutuzumab | A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02538614 | Phase Ib/II | BI 836826 + Idelalisib | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT02557516 | Phase Ib/II | Ibrutinib + Monalizumab | Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT02580552 | Phase I | MRG-106 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | Completed | USA | 0 |
NCT02611908 | Phase I | Ibrutinib + Obinutuzumab | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | Withdrawn | 0 | |
NCT02612311 | Phase III | Ublituximab Chlorambucil + Obinutuzumab Umbralisib | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | Terminated | USA | POL | ITA | ISR | GBR | ESP | 1 |
NCT02639910 | Phase II | Tafasitamab-cxix + Venetoclax Idelalisib + Tafasitamab-cxix | Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) | Completed | USA | POL | ITA | GBR | DEU | AUT | 0 |
NCT02649387 | Phase II | Ibrutinib | Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT) | Active, not recruiting | USA | 0 |
NCT02656303 | Phase II | Ublituximab + Umbralisib | An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 | Terminated | USA | POL | ITA | GBR | 0 |
NCT02684617 | Phase I | Dinaciclib + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) | Terminated | 0 | |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02717611 | Phase II | Acalabrutinib | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | Active, not recruiting | USA | ISR | GBR | FRA | ESP | BEL | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02733042 | Phase Ib/II | Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) | Completed | USA | NLD | ITA | GBR | FRA | DEU | 1 |
NCT02742090 | Phase II | Umbralisib | Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | Terminated | USA | 0 |
NCT02743546 | Phase I | Ibrutinib + JNJ-64052781 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma | Withdrawn | 0 | |
NCT02756611 | Phase III | Venetoclax | A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor (VENICE I) | Completed | USA | TUR | SWE | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUT | 2 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02801578 | Phase I | Ibrutinib | A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02846623 | Phase II | Atezolizumab + Obinutuzumab + Venetoclax | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | Recruiting | USA | 0 |
NCT02860676 | Phase I | Cirmtuzumab | Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | Completed | USA | 0 |
NCT02869633 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |
NCT02912754 | Phase Ib/II | Ibrutinib Ibrutinib + Ruxolitinib | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | Unknown status | CAN | 0 |
NCT02914327 | Phase I | Ibrutinib + SNX-5422 | Safety and Activity of SNX-5422 Plus Ibrutinib in CLL | Withdrawn | USA | 0 |
NCT02948283 | Phase 0 | Metformin + Ritonavir | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT02970318 | Phase III | Bendamustine + Idelalisib + Rituximab Acalabrutinib | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | Active, not recruiting | USA | SWE | SVK | POL | NZL | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUT | AUS | 6 |
NCT02973399 | Phase I | Ibrutinib + SNX-5422 | Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | Terminated | USA | 0 |
NCT03010358 | Phase Ib/II | Entospletinib + Obinutuzumab | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03037645 | Phase Ib/II | Vecabrutinib | Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers | Terminated | USA | 0 |
NCT03041636 | Phase II | Ruxolitinib | Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT03045328 | Phase Ib/II | Ibrutinib + Venetoclax | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL | Completed | USA | 0 |
NCT03056339 | Phase Ib/II | Cyclophosphamide + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | Completed | USA | 0 |
NCT03069469 | Phase I | Vimseltinib | Study of DCC-3014 in Patients With Advanced Malignancies | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03128879 | Phase II | Acalabrutinib + Venetoclax Ibrutinib + Venetoclax | Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL | Recruiting | USA | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03153202 | Phase Ib/II | Ibrutinib + Pembrolizumab | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | Recruiting | USA | 0 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03207256 | Phase II | Ublituximab + Umbralisib Umbralisib | Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | Terminated | USA | 0 |
NCT03207555 | Phase II | Ibrutinib | Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT03219450 | Phase I | NeoVax Cyclophosphamide + NeoVax | A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naive, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia. | Recruiting | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03265717 | Phase II | INVAC-1 | DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT03283137 | Phase I | Pembrolizumab + Umbralisib | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL | Active, not recruiting | USA | 0 |
NCT03331198 | Phase Ib/II | Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Recruiting | USA | CAN | 0 |
NCT03336333 | Phase III | Venetoclax + Zanubrutinib Zanubrutinib Bendamustine + Rituximab | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA) | Active, not recruiting | USA | SWE | POL | NZL | ITA | GBR | FRA | ESP | CZE | BEL | AUT | AUS | 3 |
NCT03370185 | Phase II | Duvelisib | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Withdrawn | USA | 0 |
NCT03379051 | Phase Ib/II | Ublituximab + Umbralisib + Venetoclax | Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL | Terminated | USA | 0 |
NCT03400176 | Phase I | Ibrutinib + VAY736 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | Terminated | USA | 0 |
NCT03406156 | Phase III | Bendamustine + Obinutuzumab Obinutuzumab + Venetoclax Bendamustine | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | Completed | USA | 0 |
NCT03422393 | Phase I | Ibrutinib + Venetoclax Venetoclax | Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib | Active, not recruiting | USA | 0 |
NCT03447808 | Phase I | Daratumumab + Ibrutinib | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03454165 | Phase I | BNC105P + Ibrutinib | A Study of BNC105P Combined With Ibrutinib | Completed | USA | 0 |
NCT03462719 | Phase III | Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW) | Active, not recruiting | USA | TUR | SWE | POL | NLD | ISR | GBR | FRA | ESP | DNK | CZE | CAN | BEL | 1 |
NCT03467867 | Phase II | Hyaluronidase + Rituximab + Venetoclax Rituximab + Venetoclax | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Active, not recruiting | USA | 0 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03513562 | Phase II | Ibrutinib + Venetoclax | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | Active, not recruiting | USA | 0 |
NCT03514017 | Phase II | Ibrutinib + Pembrolizumab | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | Terminated | USA | 0 |
NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
NCT03534323 | Phase Ib/II | Duvelisib + Venetoclax | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL | Active, not recruiting | USA | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT03579888 | Phase I | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine | CD19-Specific T Cells Post AlloSCT | Terminated | USA | 0 |
NCT03580928 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) | Active, not recruiting | USA | 0 |
NCT03601819 | Phase I | Pacritinib | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Terminated | USA | 0 |
NCT03609593 | Phase II | Rituximab Bendamustine + Rituximab Venetoclax | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03624036 | Phase Ib/II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) | Terminated | USA | ITA | 0 |
NCT03639324 | Phase I | Idelalisib + Rituximab + Venetoclax | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL (RIVe-CLL) | Withdrawn | 0 | |
NCT03671590 | Phase I | Edralbrutinib Edralbrutinib + Ublituximab + Umbralisib | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | Terminated | POL | AUS | 0 |
NCT03701282 | Phase III | Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab + Venetoclax | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ISR | 0 |
NCT03734198 | Phase II | Daratumumab + Ibrutinib | Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) | Active, not recruiting | FRA | 0 |
NCT03737981 | Phase III | Ibrutinib + Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab | Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03739554 | Phase I | CYC065 + Venetoclax | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL | Completed | USA | 0 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | SWE | POL | ITA | GBR | FRA | CHE | AUS | 2 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03759184 | Phase I | Obinutuzumab + rhIL-15 | Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | Terminated | USA | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03766763 | Phase II | Venetoclax | Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A | Active, not recruiting | FRA | 0 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | 0 |
NCT03788291 | Phase II | Acalabrutinib + Rituximab | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | Completed | USA | 0 |
NCT03801525 | Phase II | Ublituximab + Umbralisib + Venetoclax | Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination With Venetoclax in Subjects With CLL (ULTRA-V) | Terminated | USA | 0 |
NCT03807063 | Phase I | Rimiducid Rivogenlecleucel | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03824483 | Phase II | Obinutuzumab + Venetoclax + Zanubrutinib | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | Recruiting | USA | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Completed | USA | 0 |
NCT03836261 | Phase III | Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY) | Active, not recruiting | USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG | 6 |
NCT03853616 | Phase Ib/II | MB-CART19.1 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Recruiting | DEU | 0 |
NCT03893682 | Phase I | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |
NCT03900598 | Phase I | JNJ-67856633 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ITA | ISR | GRC | GBR | FRA | ESP | DEU | AUS | 3 |
NCT03943342 | Phase II | Ibrutinib Ibrutinib + Venetoclax | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | Withdrawn | 0 | |
NCT03960840 | Phase I | Ibrutinib + YTB323 YTB323 | CD19-specific CAR-T Cells in CLL/SLL and DLBCL | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
NCT03986034 | Phase II | Venetoclax | Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04008706 | Phase III | Acalabrutinib | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) | Active, not recruiting | USA | SWE | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BRA | AUS | 3 |
NCT04010968 | Phase II | Ibrutinib + Venetoclax Cyclophosphamide + Fludarabine + Rituximab | Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC) | Active, not recruiting | FRA | 0 |
NCT04016805 | Phase II | Ublituximab + Umbralisib + Venetoclax Ibrutinib + Ublituximab + Umbralisib | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib or Venetoclax | Terminated | USA | 0 |
NCT04029038 | Phase Ib/II | CD19/CD22 CAR T cells | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | Withdrawn | USA | 0 |
NCT04043845 | Phase I | Ibrutinib + LY3214996 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Withdrawn | 0 | |
NCT04116437 | Phase II | Zanubrutinib | A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib | Recruiting | USA | 0 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Completed | USA | 0 |
NCT04149821 | Phase II | Ublituximab + Umbralisib | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | Terminated | USA | 0 |
NCT04155840 | Phase II | Bendamustine + Copanlisib + Rituximab | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04163718 | Phase II | Umbralisib | TGR-1202 (Umbralisib) in Treatment Naive Patients With Chronic Lymphocytic Leukemia (CLL) | Terminated | USA | 0 |
NCT04169737 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04178798 | Phase III | Acalabrutinib | Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia | Unknown status | ESP | 0 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT04209621 | Phase II | Duvelisib + Ibrutinib | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04210219 | Phase I | JNJ-64264681 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Active, not recruiting | USA | POL | GBR | 4 |
NCT04230304 | Phase II | Daratumumab + Ibrutinib | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study | Active, not recruiting | USA | 0 |
NCT04240704 | Phase I | JBH492 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | Terminated | ISR | FIN | ESP | DEU | 3 |
NCT04245722 | Phase I | Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab Cyclophosphamide + Fludarabine + FT596 Cyclophosphamide + Fludarabine + FT596 + Rituximab | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Terminated | USA | 0 |
NCT04269902 | Phase III | Obinutuzumab + Venetoclax | Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study | Recruiting | USA | CAN | 0 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04285567 | Phase III | Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO) | Active, not recruiting | USA | ITA | FRA | ESP | AUS | 0 |
NCT04305444 | Phase II | DTRMWXHS-12 + Everolimus + Pomalidomide | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |
NCT04358458 | Phase Ib/II | GEN3009 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Terminated | USA | NLD | ESP | DNK | BEL | 0 |
NCT04419389 | Phase Ib/II | Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | Terminated | USA | 0 |
NCT04419519 | Phase II | Venetoclax | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | Recruiting | USA | 0 |
NCT04447768 | Phase II | Obinutuzumab + Venetoclax | The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | 0 |
NCT04502394 | Phase Ib/II | Acalabrutinib + KRT-232 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Unknown status | USA | POL | ITA | GBR | FRA | CZE | CHE | BEL | AUS | 2 |
NCT04509700 | Phase II | Parsaclisib Itacitinib + Parsaclisib | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DNK | CZE | BEL | AUT | 2 |
NCT04512105 | Phase I | Azacitidine + Pitavastatin + Venetoclax Decitabine + Pitavastatin + Venetoclax Pitavastatin + Venetoclax | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04515238 | Phase II | Bendamustine + Obinutuzumab + Venetoclax + Zanubrutinib | Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG) | Active, not recruiting | DEU | 0 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT04560322 | Phase II | Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab + Venetoclax | Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL | Recruiting | USA | 0 |
NCT04599634 | Phase I | Hu5F9-G4 + Obinutuzumab + Venetoclax | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | Completed | USA | 0 |
NCT04608318 | Phase III | Ibrutinib Ibrutinib + Venetoclax Obinutuzumab + Venetoclax | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17) | Active, not recruiting | SWE | NOR | NLD | ITA | ISR | IRL | FIN | ESP | DNK | DEU | CHE | BEL | AUT | 0 |
NCT04623541 | Phase Ib/II | Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUS | 0 |
NCT04624633 | Phase II | Acalabrutinib + Ublituximab + Umbralisib | AU2 In Relapsed and Untreated CLL | Active, not recruiting | USA | 0 |
NCT04657094 | Phase II | Acalabrutinib | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT04657224 | Phase I | JNJ-64264681 + JNJ-67856633 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Active, not recruiting | USA | POL | NLD | ISR | FRA | ESP | BEL | AUS | 4 |
NCT04660045 | Phase II | Acalabrutinib | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Withdrawn | USA | 0 |
NCT04679012 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | Recruiting | USA | 0 |
NCT04684108 | Phase I | SG301 | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | Active, not recruiting | 1 | |
NCT04684563 | Phase I | HuCART19-IL18 | huCART19-IL18 in NHL/CLL Patients | Recruiting | USA | 0 |
NCT04685915 | Phase II | Copanlisib + Ibrutinib | Copanlisib Plus Ibrutinib in R/R CLL | Withdrawn | 0 | |
NCT04722172 | Phase II | Acalabrutinib + Obinutuzumab | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | Active, not recruiting | USA | 0 |
NCT04771507 | Phase Ib/II | Ibrutinib | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) (IbruOnOff) | Recruiting | SWE | NOR | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04781855 | Phase I | Ibrutinib + Ipilimumab Ibrutinib + Ipilimumab + Nivolumab | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | Active, not recruiting | USA | 0 |
NCT04806035 | Phase I | TG-1801 + Ublituximab TG-1801 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |
NCT04876092 | Phase I | Ibrutinib + JNJ-67856633 | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in B-cell NHL and CLL | Active, not recruiting | SWE | POL | FRA | DNK | 0 |
NCT04883749 | Phase II | Acalabrutinib | Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail) | Active, not recruiting | DEU | AUT | 0 |
NCT04892277 | Phase I | Bendamustine IC19/1563 Cyclophosphamide + Fludarabine | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT04895436 | Phase II | Obinutuzumab + Venetoclax | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | ROU | ITA | ISR | GBR | ESP | DEU | BRA | BGR | AUT | AUS | 0 |
NCT04978779 | Phase I | VIP152 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | Terminated | USA | POL | 0 |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Unknown status | USA | AUS | 1 |
NCT05005299 | Phase I | Cyclophosphamide + Fludarabine + Venetoclax | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) | Recruiting | AUS | 0 |
NCT05091424 | Phase I | Mosunetuzumab-axgb + Tocilizumab | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05168904 | Phase Ib/II | CYC065 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | Suspended | USA | 0 |
NCT05211336 | Phase I | Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | Active, not recruiting | USA | 0 |
NCT05293912 | Phase I | SG2501 | SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. | Recruiting | USA | 0 |
NCT05317936 | Phase II | Pirtobrutinib + Venetoclax | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | Active, not recruiting | USA | 0 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05405309 | Phase Ib/II | Olaparib + RP-3500 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) | Terminated | USA | 0 |
NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |
NCT05458297 | Phase II | VLS-101 ARQ 531 + VLS-101 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Recruiting | USA | TUR | SWE | POL | ITA | ISR | IRL | GBR | EST | ESP | DEU | CZE | CAN | BRA | 7 |
NCT05478512 | Phase II | Obinutuzumab + Venetoclax + Zanubrutinib Obinutuzumab + Venetoclax | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (VIS) | Recruiting | ITA | 0 |
NCT05487651 | Phase I | KUR-502 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2) | Recruiting | USA | 0 |
NCT05512390 | Phase I | ABBV-319 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | ISR | CAN | AUS | 0 |
NCT05515406 | Phase I | ONO-7018 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | Recruiting | USA | 0 |
NCT05537766 | Phase II | Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) | Active, not recruiting | USA | NLD | ITA | FRA | ESP | DEU | CHE | AUT | 0 |
NCT05618028 | Phase I | ABBV-525 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT05705570 | Phase I | Cyclophosphamide + Fludarabine MB-CART19.1 | A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1) | Not yet recruiting | BRA | 0 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05873712 | Phase II | Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05908409 | Phase Ib/II | IDP-121 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | Recruiting | ESP | 0 |
NCT05943496 | Phase I | Acalabrutinib + Obinutuzumab + Tafasitamab-cxix | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |
NCT05971251 | Phase I | Acalabrutinib + Loncastuximab tesirine-lpyl | Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Study of Tazemetostat in Lymphoid Malignancies | Recruiting | USA | 0 |
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |
NCT06073821 | Phase III | Obinutuzumab + Venetoclax BGB-11417 + Zanubrutinib | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | TUR | SWE | POL | NZL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUT | AUS | 3 |
NCT06227026 | Phase I | Anti-CD19 CAR-T cells | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) | Recruiting | USA | 0 |
NCT06333262 | Phase II | Obinutuzumab + Pirtobrutinib Pirtobrutinib | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT06428019 | Phase III | Obinutuzumab + Venetoclax Acalabrutinib + Venetoclax | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 1 |
NCT06520098 | Phase II | Ibrutinib Zanubrutinib Ibrutinib + Venetoclax Venetoclax + Zanubrutinib Acalabrutinib Acalabrutinib + Venetoclax | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (Benefit VA) | Not yet recruiting | USA | 0 |
NCT06524375 | Phase II | Acalabrutinib + Venetoclax Ibrutinib + Venetoclax Venetoclax + Zanubrutinib | A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period (BRAVE) | Recruiting | USA | 0 |
NCT06542250 | Phase Ib/II | AZD5492 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS | 1 |
NCT06644183 | Phase Ib/II | Rituximab + Venetoclax IOA-244 + Rituximab + Venetoclax | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | Not yet recruiting | USA | 0 |
NCT06651970 | FDA approved | Obinutuzumab Zanubrutinib Rituximab Acalabrutinib Venetoclax | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | Not yet recruiting | USA | POL | ITA | GBR | ESP | CZE | 0 |